These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25249327)

  • 1. Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring.
    Zabotti A; Baraldo M; Quartuccio L; Sacco S; De Marchi G; De Vita S
    Clin Rheumatol; 2015 Jan; 34(1):171-4. PubMed ID: 25249327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil.
    Daleboudt GM; Reinders ME; den Hartigh J; Huizinga TW; Rabelink AJ; de Fijter JW; Berger SP
    Lupus; 2013 Feb; 22(2):171-9. PubMed ID: 23257398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis.
    Kittanamongkolchai W; Rukrung C; Supasiri T; Lertjirachai I; Somparn P; Chariyavilaskul P; Avihingsanon Y
    Lupus; 2013 Jun; 22(7):727-32. PubMed ID: 23651860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring.
    Łuszczyńska P; Pawiński T; Kunicki PK; Durlik M; Augustyniak-Bartosik H; Hurkacz M
    Eur J Clin Pharmacol; 2019 Mar; 75(3):371-379. PubMed ID: 30430214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen.
    Fujinaga S; Ohtomo Y; Hara S; Umino D; Someya T; Shimizu T; Kaneko K
    Pediatr Nephrol; 2008 Oct; 23(10):1877-82. PubMed ID: 18414900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
    Kaczmarek I; Bigdeli AK; Vogeser M; Mueller T; Beiras-Fernandez A; Kaczmarek P; Schmoeckel M; Meiser B; Reichart B; Ueberfuhr P
    Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis.
    Godron-Dubrasquet A; Woillard JB; Decramer S; Fila M; Guigonis V; Tellier S; Morin D; Sordet M; Saint-Marcoux F; Harambat J
    Pediatr Nephrol; 2021 Feb; 36(2):341-347. PubMed ID: 32856157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.
    Djabarouti S; Duffau P; Lazaro E; Chapouly C; Greib C; Viallard JF; Pellegrin JL; Saux MC; Breilh D
    Expert Opin Pharmacother; 2010 Apr; 11(5):689-99. PubMed ID: 20210680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses.
    Kamar N; Marquet P; Gandia P; Muscari F; Lavayssière L; Esposito L; Guitard J; Canivet C; Peron JM; Alric L; Suc B; Saint-Marcoux F; Rostaing L
    Ther Drug Monit; 2009 Aug; 31(4):451-6. PubMed ID: 19531983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study.
    Alexander S; Fleming DH; Mathew BS; Varughese S; Jeyaseelan V; Tamilarasi V; Jacob CK; John GT
    Ther Drug Monit; 2014 Aug; 36(4):423-32. PubMed ID: 25014074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan.
    Yasuda S; Atsumi T; Shimamura S; Ono K; Hiromura K; Sada K; Mori M; Takei S; Kawaguchi Y; Tamura N; Takasaki Y
    Mod Rheumatol; 2015; 25(6):854-7. PubMed ID: 25800636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
    Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
    Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis.
    Romano-Aguilar M; Reséndiz-Galván JE; Medellín-Garibay SE; Milán-Segovia RDC; Martínez-Martínez MU; Abud-Mendoza C; Romano-Moreno S
    Lupus; 2020 Aug; 29(9):1067-1077. PubMed ID: 32539658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
    Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
    Contreras G; Tozman E; Nahar N; Metz D
    Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis.
    Abd Rahman AN; Tett SE; Abdul Gafor HA; McWhinney BC; Staatz CE
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):993-1004. PubMed ID: 28536776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus.
    Weng MY; Weng CT; Liu MF
    Clin Rheumatol; 2010 Jul; 29(7):771-5. PubMed ID: 20195879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.
    Houssiau FA; D'Cruz D; Sangle S; Remy P; Vasconcelos C; Petrovic R; Fiehn C; de Ramon Garrido E; Gilboe IM; Tektonidou M; Blockmans D; Ravelingien I; le Guern V; Depresseux G; Guillevin L; Cervera R;
    Ann Rheum Dis; 2010 Dec; 69(12):2083-9. PubMed ID: 20833738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study.
    Laskari K; Mavragani CP; Tzioufas AG; Moutsopoulos HM
    Arthritis Res Ther; 2010; 12(6):R208. PubMed ID: 21059275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.